ArticleFrontiers in aging neuroscience2026
Esketamine ameliorates postoperative cognitive dysfunction aggravated by preoperative acute sleep deprivation in aged mice via the TLR4/NF-κB pathway.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- USF1-mediated transcription of PARP1 contributes to sevoflurane-induced pyroptosis in perioperative neurocognitive disorders.Functional & integrative genomics · 2026Article
- Neuroinflammation in postoperative cognitive dysfunction: the multi-target potential of esketamine in modulating microglial responses and synaptic integrity.Frontiers in molecular neuroscience · 2026Review
- Clinical research progress of esketamine in perioperative neuroprotection: from mechanisms to therapeutic neuroprotection.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Postoperative cognitive dysfunction (POCD) is a common complication in elderly patients, and preoperative sleep deprivation may exacerbate its severity. Although earlier research has confirmed that esketamine can reduce the incidence of POCD, it remains unclear whether it is effective against POCD exacerbated by preoperative acute sleep deprivation. The present study is designed to examine the protective role and intrinsic mechanisms through which esketamine acts on POCD aggravated by pro operative acute sleep deprivation prior to surgery. Methods: The modified multiple platform method was employed to induce acute sleep deprivation, and the POCD model was established through left lateral lobectomy of the liver after 48 h of sleep deprivation. Esketamine was administered 30 min postoperatively. The Open Field Test and Morris Water Maze were utilized to assess postoperative cognitive alterations. Hippocampal pathology results were examined via hematoxylin-eosin staining; the concentrations of key inflammatory cytokines, namely interleukin-6 (IL-6), IL-1β, and tumor necrosis factor- Results: Esketamine administration post surgery significantly ameliorated cognitive deficits aggravated by preoperative acute sleep deprivation in aged mice. Concomitantly, esketamine downregulated the expression of TLR4, MyD88, and phosphorylated NF-κB p65 in hippocampal microglia, reduced hippocampal levels of IL-6, IL-1β, and TNF-α, and alleviated hippocampal tissue injury. Conclusion: Esketamine exerts neuroprotective effects against POCD exacerbated by preoperative acute sleep deprivation in aged mice by inhibiting the TLR4/NF-κB signaling pathway in hippocampal microglia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.